Home › Epilepsy › Ohio › Columbus
Epilepsy clinical trials in Columbus, OH
4 studies for Epilepsy are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
RecruitingPhase 1/2
- Ohio State University, Columbus
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
RecruitingPhase 3
- The Ohio State University, Columbus
- OhioHealth Riverside Methodist Hospital, Columbus
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
RecruitingObservational study
- Nationwide Children's, Columbus
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RecruitingPhase 3
- OhioHealth, Columbus
About Epilepsy
Epilepsy is a brain disorder that causes people to have seizures. The seizures may be mild or severe. Learn about causes, diagnosis, and treatment.
More about Epilepsy on MedlinePlus
Epilepsy trials in other cities
- Boston, MA19 studies
- Houston, TX16 studies
- New York City, NY13 studies
- Washington, DC12 studies
- Philadelphia, PA11 studies
- Cleveland, OH9 studies
- Phoenix, AZ9 studies
- Durham, NC8 studies
- Rochester, MN8 studies
- Birmingham, AL7 studies
- Mountain View, CA7 studies
- St. Louis, MO7 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer56 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Cancer (all types)38 studies
- Lung Cancer37 studies
- Acute Myeloid Leukemia35 studies
- Chronic Lymphocytic Leukemia28 studies
- Metastatic Cancer27 studies
- Endometrial Cancer25 studies
- Colorectal Cancer24 studies
- Prostate Cancer24 studies
- Multiple Myeloma24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.